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Abstract
Background: Farnesyltransferase inhibitors (FTIs) are anticancer agents developed to inhibit Ras oncoprotein
activities. FTIs of different chemical structure act via a conserved mechanism in eukaryotic cells. They have low
toxicity and are active on a wide range of tumors in cellular and animal models, independently of the Ras
activation state. Their ultimate mechanism of action, however, remains undetermined. FTase has hundred of
substrates in human cells, many of which play a pivotal role in either tumorigenesis or in pro-survival pathways.
This lack of knowledge probably accounts for the failure of FTIs at clinical stage III for most of the malignancies
treated, with the notable exception of haematological malignancies. Understanding which cellular pathways are
the ultimate targets of FTIs in different tumor types and the basis of FTI resistance is required to improve the
efficacy of FTIs in cancer treatment.
Results: Here we used a yeast-based cellular assay to define the transcriptional changes consequent to FTI
peptidomimetic administration in conditions that do not substantially change Ras membrane/cytosol distribution.
Yeast and cancer cell lines were used to validate the results of the network analysis. The transcriptome of yeast
cells treated with FTase inhibitor I was compared with that of untreated cells and with an isogenic strain
genetically inhibited for FTase activity (Δram1). Cells treated with GGTI-298 were analyzed in a parallel study to
validate the specificity of the FTI response. Network analysis, based on gene ontology criteria, identified a cell cycle
gene cluster up-regulated by FTI treatment that has the Aurora A kinase IPL1 and the checkpoint protein MAD2 as
hubs. Moreover, TORC1-S6K-downstream effectors were found to be down-regulated in yeast and mammalian FTI-
treated cells. Notably only FTIs, but not genetic inhibition of FTase, elicited up-regulation of ABC/transporters.
Conclusions: This work provides a view of how FTIs globally affect cell activity. It suggests that the chromosome
segregation machinery and Aurora A association with the kinetochore as well as TORC1-S6K downstream effectors
are among the ultimate targets affected by the transcriptional deregulation caused by FTI peptidomimetics.
Moreover, it stresses the importance of monitoring the MDR response in patients treated with FTIs.
Background
Farnesyl transferase (FTase) and Geranylgeranyl trans-
ferase I (GGTase I) are heterodimeric enzymes that cat-
alyze the transfer of C-15 or C-20 lipid moieties,
respectively, to the C-terminal cysteine of proteins hav-
ing CAAX motifs at their C-terminus, the last amino
acid discriminating among the two enzyme substrates
[1]. The observation that Ras oncoproteins require far-
nesylation for membrane binding and malignant activity
led to the development of drugs targeting FTase. As
FTase structure and function has been conserved
throughout evolution, the first farnesyl transferase inhi-
bitor, Manumycin A, was selected using a yeast-based
screening system [2]. Over the past decade, improved
chemically-synthesized FTase and GGTase I inhibitors
(FTI and GGTI, respectively) were tested in preclinical
models. Surprisingly, they were active on a wide range
of tumors independently of their Ras oncogenic status.
Nowadays, it is clear that there are hundreds of FTase
substrates and the wide spectrum of action of FTIs
arises from the large number of farnesylated proteins
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acting at different levels in oncogenic pathways and pro-
survival pathways [3].
Although preclinical studies showed that FTIs induce
tumor growth inhibition rather than tumor regression
and their ultimate targets in cells remained largely unde-
fined, they entered clinical trials. Promisingly, FTIs
synergize with taxanes and show some efficacy in the
treatment of breast cancer when administrated in com-
binatorial therapy. Unfortunately, when administrated as
a single agent, they failed clinical trials at stage III for
most of the malignancies tested, with the notable excep-
tion of haematological malignancies. This failure has
been largely attributed to the scarce knowledge of how
FTIs ultimately act in the cell [4-9].
Collectively, clinical and preclinical studies have
shown that FTIs are anti-proliferative agents that have
low toxicity for normal cells. Moreover, the efficacy of
structurally diverse FTI molecules is highly consistent in
different organisms, showing that they act via a con-
served mechanism in eukaryotic cells [5,8]. Proteomic
approaches aimed at identifying proteins differentially
prenylated upon FTI treatment have shown that, in
addition to Ras oncoproteins, DNAJ, laminin A, nucleo-
some assembly protein NAP-1, peroxisomal biogenesis
factor 1 and annexin are differentially prenylated using
FTIs at clinically relevant dosages [10]. More classical
biochemical approaches related FTI anti-proliferative
action to defects in the attachment of farnesylated pro-
teins, such as CENP-E and CENP-F, to kinetochores
[11-13] or poor prenylation of RheB [3]. Unfortunately,
the correct minimal balance of farnesylated and non-far-
nesylated proteins within cells is often unknown. Taken
together, these approaches have been unable so far to
clearly correlate the FTI antiproliferative action with the
prenylation status of a given protein basically due to: i)
the large number of farnesylated proteins in human
cells; ii) their multiple roles in different processes lead-
ing to proliferation and, last but not least, iii) the diffi-
culty in correlating the lack of prenylation of an FTase
target with the FTI antiproliferative action [4,14].
To predict FTI efficacy at the clinical level it is neces-
sary to devise novel genomic strategies to further deci-
pher how FTIs ultimately affect cellular activity. Which
off-targets they might affect and how FTI resistance is
achieved are major challenges for today’s studies. Pro-
mising results towards the goal of predicting FTI effi-
cacy in clinical practice were recently reported by
profiling the expression signatures of newly diagnosed
Acute myelogenous leukemia (AML) patients treated
with TIPIFARNIB (Zarnestra). The ratio of expression
levels of two genes, RASGRP and APTX, appears to be
predictive of the Tipifarnib response in AML patients,
although it remains unclear how this might operate
[3,8,15].
From the above it is clear that a better knowledge of
FTI action at the cellular level is required. Here we have
used a yeast genetics strategy and FTI peptidomimetics
administrated at dosages that do not appreciably affect
Ras cytosolic/membrane distribution to identify the net-
work of proteins transcriptionally deregulated by this
class of drug. Network analysis and follow-up studies
were performed in yeast and in mammalian cancer cell
lines using biochemical approaches and high-throughput
high-content image analysis. Collectively, the results
indicate that the ultimate peptidomimetic FTI targets
are proteins in the nucleus acting at the kinetochore
having as hubs the Aurora A and MAD2 proteins. We
show that Aurora A is indeed mislocalised in HeLa cells
upon treatement with the FTI peptidomimetic FTI-277.
Furthermore, we show that proteins acting at the cross-
roads of the Ras/PKA and TORC/S6K pathways are
down-regulated in yeast genetically impaired in FTase
activity or treated with an FTI peptidomimetic. Consis-
tent with this, HeLa and MCF-7 cells show poor phos-
phorylation of the ribosomal S6 protein, a target of
TORC/S6K during starvation. Moreover, we show that a
FTI peptidomimetic up-regulated the MDR gene
response.
Results and Discussion
Basic assumptions and set-up of the assay conditions
It is well established that the basic components of the
prenylation, transcriptional, cell cycle and trafficking
machineries are conserved between yeast and humans.
Moreover, S. cerevisiae has proven to be a powerful
genetic tool to elucidate the mode of action of clinically
relevant compounds at the genomic level [16-19]. We
reasoned that if there is a basic common mechanism by
which FTIs act as antitumor agents in eukaryotic cells
[3,5,8,20] then this mechanism could be identified in
yeast cells based solely on FTase activity inhibition and
the results reciprocated in mammalian cells, irrespective
of the FTI compound used in the two organisms.
Human and yeast FTases are conserved in structure
and function. They are constituted by two subunits,
called RAM1 and RAM2 in yeast cells. The b subunit
RAM2 is shared with GGTase I, while the alpha subunit
is specific for each enzyme, RAM1 for FTase and
CDC43 for GGTase I [1]. Importantly, for the aims of
this study, cells deleted for the RAM1 gene (Δram1) are
viable as essential proteins, that cannot be farnesylated
in the absence of FTase activity, are geranylgeranylated
by GGTase I. Thus, budding yeast provides a unique
genetic tool to decipher the global response to FTIs and
to prove that FTI antiproliferative action relies solely on
the inhibition of FTase activity.
To define the expression signature of FTI- or GGTI-
treated yeast cells we chose well-studied and commercially
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available compounds. All of them had been already
tested for their antiproliferative action in cancer cell
lines. To be suitable for our study, we applied the fol-
lowing constraints. The compound should: 1) be cell
permeable (to be administrated in the growth media);
2) be already demonstrated to possess a higher specifi-
city either for FTase or GGTase I in a mammalian cel-
lular system; 3) be active, as an anti-proliferative drug,
at the same concentration in yeast and mammalian
cells. Moreover, we were interested to study the effects
on transcription independently of Ras. Thus we
searched for an FTI concentration that could elicit an
antiproliferative action in yeast and in mammalian
cells without substantially affecting Ras membrane/
cytosolic distribution.
Based on the above criteria, the commercially available
FTIs we tested were the FTase inhibitor I (N-[2(S)-[2
(R)-Amino-3-mercaptopropylamino]-3-methylbutyl]-
Phe-Met-OH) and FTI-277 (Merck-Calbiochem) and as
a GGTase inhibitor GGTI-298 (Merck-Calbiochem).
According to the manufactures, FTase inhibitor I and
FTI-277 are peptidomimetics that exert an antiprolifera-
tive action in human tumor cell lines at concentrations
above 21 nM. In experimental work these compounds
are generally used at a concentration range between 0.5-
10 μM [21-24].
To set up the appropriate cell assay conditions that
fulfill the above-mentioned criteria, we tested FTase
inhibitor I and FTI-277 in parallel with the antibiotic
Manumicyn A (Merk-Calbiochem). Manumycin A, an
FTI that was selected in yeast cells, has poor specificity
for either FTase or GGTase I [2].
Summarising a large number of growth tests that were
performed with different concentrations ranging from 1
to 30 μM of FTI-277, FTase inhibitor I and Manumycin
A in liquid synthetic complete media (SCD) or rich
liquid media (YPD) containing 2% glucose, we found
that 10 μM Manumycin A was sufficient to reduce the
doubling time of yeast cells with different genetic back-
grounds (Table 1: K699, W303 and BY4741) in SCD.
The duplication time of the BY4741 strain is signifi-
cantly reduced in the presence of 10 μM Manumycin A
or 10 μM FTase inhibitor I, but is not affected by the
use of similar dosages of FTI-277 or GGTI-298 (Fig. 1A
and data not shown). As expected, Δram1 BY4741 cells,
lacking FTase activity due to deletion of the RAM1
gene, are not affected by a 10 μM concentration of FTIs
(Figure 1A) while Manumycin A shows some toxicity in
this strain as it also targets GGTase I (data not shown).
The strain K699, a derivative of strain W303, showed
some degree of sensitivity with an average duplication
time of 84 min in the absence of FTase inhibitor I and
98 min with 10 μM FTase inhibitor I, 119 min in the
presence of Manumicyn A, but was not affected by FTI-
277 or GGTI-298.
In summary, all strain backgrounds tested are sensitive
to 10 μM Manumycin A in SCD liquid media. The aver-
age replication time during the exponential phase of
growth of strains BY4741 and K699 is slower in the pre-
sence of 10 μM FTase inhibitor I. No effect on the repli-
cation of any tested yeast strain was observed upon
addition of 10 μM FTI-277 or GGTI-298. Based on
these tests we chose 10 μM FTase inhibitor I to add to
liquid media and the yeast strain BY4741 and its iso-
genic Δram1 derivative (EUROSCARF) for this study.
To determine if FTase inhibitor I alters Ras membrane
binding, BY4741 and Δram1 cells expressing GFP-Ras2p
were treated or not with 10 μM FTase inhibitor I in par-
allel experiments. The amount of GFP-Ras2p bound to
intracellular membranes or in the cytosol was examined
by immunoblot analysis, using an anti-GFP antibody, of
cell extracts fractionated by differential centrifugation. A
marked reduction in the amount of GFP-Ras2p bound
to intracellular membranes was clearly observed in
Δram1 cells compared to untreated BY4741 cells (Figure
1B, panel aGFP P15400 × g). FTI treatment did not
change the amounts of GFP-Ras2p bound to intracellu-
lar membranes either in BY4741 or Δram1 cells (Figure
1B, panel aGFP). Fluorescence microscopy analysis of
the cells prior to fractionation corroborated these data
(Figure 1C).
Thus, 10 μM of the FTase inhibitor I peptidomimetic:
a) reduces the duplication time during exponential
growth of BY4741 but not Δram1 cells; 2) does not sub-
stantially alter the membrane/cytosol distribution of the
Ras2 protein. Unless otherwise specified, in the remain-
ing part of the paper the use of “FTI treatment” refers
to the use of 10 μM FTase inhibitor I.
The chromosome segregation and the Multidrug-
Resistance machineries are up-regulated during FTI
treatment
The effects of FTI on yeast global gene expression were
determined using commercially available dEST microar-
rays (Yeast 6.4K Array; UHN microarray Center,
Toronto Canada). Briefly, these are glass arrays double-
spotted with 6,240 unique yeast ORFs and 160 gene
controls of Arabidopsis thaliana. The information on
the spotting and experimental design of the Yeast 6.4K
Table 1 Strain list
Strains Genotype
W303-1B MATa leu2, ura3, his3, TRP1, ade2, canR /wt mit+
BY4741 MATa, leu2, ura3, his3, met15
YDL090C MATa, leu2, ura3, his3, met15, Δram1:Kanr
K699 MATa, ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3 GAL
psi+
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Arrays are available at the manufacture’s web site http://
www.microarray.ca/, detailed in the Methods section
and in the Additional file 1. We performed at least four
biological replicates per sample. Cy3/Cy5 dye-swapping
method was used to differentially label fluorescent
cDNAs obtained by reverse mRNA transcription of
FTase inhibitor-treated and untreated cells. After cDNA
labelling, mixing and hybridization the arrays were
scanned and normalised using GenePix6 software tools
(Molecular Devices). Lowess normalization was per-
formed by using the Acuity software (Molecular
Devices). Genes flagged absent (too low intensity over
background) or flagged bad were excluded from the cal-
culations. The expression levels of all genes present in
each data set was visualised using Gene@work (IBM
research; additional file 1 and 2: Figure S1, S2 and S3).
Comparing each color panel (left panels in additional
file 2 Figure: S1, S2 and S3, respectively) with the mean
expression color panel calculated for each data set (right
panel in additional figure S1, S2 and S3, respectively), it
is possible to observe an overall good reproducibility:
up-regulated and repressed genes cluster at the two
opposite sides of the color panels in each biological
replicate.
T-test of Acuity program (Molecular Devices) was
used to statistically filter the normalised data and to
obtain the statistically significant hits. Quantitative Real-
time PCR was finally used to validate ten hits, randomly
chosen among the up-regulated and down-regulated
genes of FTI treated samples (Additional file 2: Figure
S4 and Table S1).
To obtain information about the functional relation-
ships of the statistically significant hits, they were
further analysed using the Gene Ontology criteria at the
S. cerevisiae Gene Ontology (SGO) annotation database
(http://www.yeastgenome.org/GOContents.shtml, update
November 2009). Gene clusters sharing a similar ontol-
ogy category were further dissected for their network
relationship using the STRING database and related
tools at http://string.embl.de (STRING- Known and Pre-
dicted Protein-Protein Interactions, version 8.2; highest
confidence search score set 0.900, no text mining).
Using a T-test confidence score set at 80%, a total of
69 transcripts were classified as up-regulated and 35
down-regulated at least 0.5 fold upon FTI treatment
(Additional file 2: Table S2).
Binning the 69 up-regulated transcripts for compart-
ment of action, using Super GO-Slim Component at
the SGO database (Figure 2A, panel FTI), showed that
24.6% of them encode proteins that reside within the
nucleus (Additional file 2: Table S3). Of these, a statisti-
cally relevant (p < 0.01) group has a function in chro-
mosome segregation (namely, AME1, FIN1, SCC2,
CNN1, NNF1) and/or in microtubule organization
Figure 1 Effect of FTase inhibitor I on growth and Ras2 localization in wt and Δram1 cells. A, BY4741 but not Δram1 cells are sensitive to
10 μM FTase inhibitor I. Growth curves were performed in parallel cultures with or without 10 μM FTase inhibitor I. Optical density (OD600)
measurements were taken at the indicated time points. B, GFP-Ras2 localization in FTI-treated BY4741 and Δram1 cells. Total cell extracts were
clarified at 3500 × g and fractionated into cytosolic (S15400 × g) and membrane (P15400 × g) fractions as previously described [50]. 30 μg of
proteins were separated by SDS-PAGE and immunoblot analysis was performed using a-GFP (upper panels) after Ponceau S staining (lower
panels) of nitrocellulose membranes. C, Fluorescence (upper panels) and DIC (lower panels) images of cells used in (B) prior to fractionation.
Porcu et al. Molecular Cancer 2010, 9:197
http://www.molecular-cancer.com/content/9/1/197
Page 4 of 18
(namely, DAD1, FIN1, DUO1; Additional file 2: Table
S4). AME1, CNN1, DAD1, DUO1 and NNF1 share a
function at the kinetochore (Additional file 2: Table S5).
The possible relationship among the genes binned in
the cell cycle group according to GO criteria (DAD1,
DUO1, FIN1, SCC2, SPS4, SWM1; Additional file 2:
Table S6) were further dissected using STRING tools
(see above). With the exception of SPS4, the aurora
kinase IPL1 and the checkpoint protein MAD2 were
identified as possible hubs of this group (Figure 3A).
The serine-threonine kinase Aurora A controls various
mitotic events including chromosome segregation in
yeast as well as in human cells. The aurora A mRNA
varies throughout the cell cycle and peaks during G2/M.
MAD2 is a spindle-assembly checkpoint complex com-
ponent. Its activity is required to delay the onset of ana-
phase in cells with defects in mitotic spindle assembly
[25].
Thus, the clustering and network analyses of the cell
cycle group up-regulated by FTI treatment suggest that
proteins acting at the kinetochore and at the spindle-
assembly checkpoint complex are among the final tar-
gets of FTI peptidomimetics and point to the Aurora A
kinase IPL1 and the MAD2 protein at the hubs of this
transcriptional response (Figure 3A). See below for vali-
dation of this assumption in mammalian cells.
Binning of the 69 up-regulated genes by biological
process using Super GO-Slim Process tool (Figure 2B
and Additional file 2: Table S6) identifies genes regulat-
ing the transcription of plasma membrane (PM) trans-
porters as responding to FTI treatment.
The up-regulation of PDR1 and the sugar transporters
HXT16 and HXT17 (Additional file 2: Table S6) is of
note in this group, as there is a relationship between
HXT genes, ABC transporter up-regulation and drug
resistance in yeast as well as in mammals. PDR1 is the
major regulator of the expression of the PM transpor-
ters known as ATP-binding cassettes (ABC) such as
PDR5 and PDR10. ABC transporters are P-glycoproteins
(Pgp) that represent the yeast counterparts of the
human multidrug-resistance proteins (MDRs). ABC
transporters and Pgp are the major contributors to mul-
tidrug resistance by regulating drug efflux of several
unrelated compounds [26,27]. The human Pgp MDR1
functions as an efflux pump for different anticancer
agents such as anthracyclines, Vinca alkaloids, and tax-
anes [28]. The yeast hexose transporters (HXT) are
homologues of the mammalian glucose transporters
(GLUT). GLUT-1 is consistently up-regulated in cells
with K-RAS or B-RAF mutations in colorectal cancer
cell lines [29] and is responsible of enhanced glucose
uptake, glycolysis and increased survival in low-glucose
conditions in these cells. In yeast, moreover, PDR1 regu-
lates the hexose transporters HXT9 and HXT11 [30,31].
Notably, overexpression of these latter hexose transpor-
ters increases sensitivity to drugs [31,32]. In summary,
given these correlations between MDR and HXT genes
and considering the network analysis results, it is con-
ceivable to think that the up-regulation of PDR1 and
HXT genes in FTI-treated cells is part of the same cellu-
lar circuit, controlling the ability of the cells to expel
drugs via MDR activation.
To confirm that FTI treatment activates a multidrug
resistance response also at the protein level, we exam-
ined the localization of the ABC transporter PDR5,
which is transcriptionally regulated by PDR1, in treated
and untreated yeast cells. For this we used a GFP-tagged
PDR5 (GFP-PDR5) protein and as controls the general
Figure 2 Comparative gene ontology analysis. Pie representation of up-regulated genes using the gene ontology GO-Slim tool at the
Saccharomyces Gene Ontology Data base binned for (A) compartment of action and (B) biological processes. FTI, BY4741 cells treated with 10
μM FTase inhibitor I; GGTI, BY4741 cells treated with 10 μM GGTI298; Δram1, untreated YDL090C cells compared to untreated BY4741 cells.
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amino acid permease GAP1 (YKR039W; GFP-GAP1)
and the metal ion and magnesium transporter ALR1
(YOL130W; GFP-ALR1) by epifluorescence microscopy
in time-lapse experiments (Figure 4A, respective panels).
GFP-PDR5 localizes mainly at the plasma membrane
(Figure 4B, panel PM; [33]) during exponential growth
while it accumulates in endosomal and vacuolar com-
partments when cells reach stationary phase [33].
The localization of GFP-PDR5, GFP-ALR1 and GFP-
GAP1 was scored at different time points prior to and
after drug addition during the exponential growth
phase. No changes in localization of GFP-ALR1 or GFP-
GAP1 were observed 2 h after the addition of FTase
inhibitor I (Figure 4A, respective panels). Within 2 h of
FTase inhibitor I addition we observed a slight increase
in the number of cells with GFP-PDR5 in endosomal
structures (Figure 4B) that further increases when cells
are left without agitation for a further 30 min. We con-
clude that FTase inhibitor I alters PDR5 recycling from
the plasma membrane. We cannot rule out the possibi-
lity that an increase in the amount of PDR5 due to
PDR1 up-regulation after FTI treatment might cause an
“GFP-PDR5 endosomal jam” in FTI-treated cells.
To further corroborate the specific effect of FTI treat-
ment on ABC transporter expression/recycling over
other pathways, we scored several GFP (or RFP)-tagged
PM proteins as well as proteins involved in intracellular
trafficking of lipids and proteins, in vesicle and organelle
motility and/or cytokinesis in FTI-treated and untreated
cells (see list of constructs in Table 2). With the excep-
tion of PDR5, no differences in localization between
FTI-treated and untreated cells were observed for any of
the proteins listed in Table 2.
This result confirmed that FTI treatment alters the
MDR response in yeast cells at the transcriptional as
well as at the protein level.
FTI down-regulates transcripts of key components of the
TORC1-S6K pathways
Thirty-five genes were found to be down-regulated in
FTase inhibitor I-treated cells (Additional file 2: Table
S2). Among them, 8.6% share a function in the cell
cycle (FAR7, RIM15, ZIP2), and a similar percentage in
transcription (HAP5, MET18, RPA135; Table S7).
Network analysis of the cell cycle-associated RIM15,
FAR7 and ZIP2 gene cluster using the STRING software
identified the cyclin CLN2 as a hub of this protein net-
work (Additional file 2: Figure S5). The G1 cyclin
CLN2, by activating the cyclin-dependent kinase
Cdc28p, is critical for re-entry into the mitotic cell cycle
after G0 arrest and for G1/S progression during vegeta-
tive growth and after pheromone arrest. Chemically dif-
ferent FTIs were reported previously to cause such a
defect in mammalian cells [3,5].
The finding of RIM15 in the group of down-regu-
lated cell-cycle associated genes suggests an action of
FTI on the ability of cells to respond to nutrient star-
vation. RIM15 is a distinct member of the PAS kinase
Figure 3 Network analysis of the cell cycle up-regulated
transcripts in FTI-treated BY4741 and in Δram1 cells.
Confidence view image of gene clusters acting in the cell cycle and
up-regulated in (A) 10 μM FTI treated BY4741 cells and (B) Δ ram1
cells using the STRING analysis tool. Analyses were performed by
setting the confidence score at the highest confidence (score =
0.900) and excluding text mining. Asterisks with a red arrow indicate
the input proteins. The position of nodes CDC28, MAD2, IPL1 and
RPB1 within the network is highlighted.
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family regulating cell growth and division in response
to RAS/PKA and/or TOR/SCH9 signalling networks,
through the transcription factors Msn2/4 and Gis1
(Additional file 2: Figure S5; [34]). In particular,
RIM15 positively regulates proper entry into stationary
phase under nutrient starvation [34,35]. STRING net-
work analysis of the RIM15, FAR7 and ZIP2 gene clus-
ter (Additional file 2: Figure S5) shows a direct link
between RIM15 and the TORC1-responsive kinase
SCH9. The Sch9 kinase is the yeast orthologue of the
mTORC1 substrate S6K1 [36]. Similarly to the
mTORC1-S6K1 signalling pathway, it plays an essential
role in regulating life-span in response to nutritional
and environmental stress cues [36,37]. In human
tumors, hyperactivation of mTORC1, via the S6K path-
ways, leads to the hyperphosphorylation of ribosomal
S6 protein (RPS6; [38]). The evolutionary conservation
of the pathway controlled by TORC1 and S6K1 [36]
and of the FTI mode-of-action, prompted us to test if
FTI peptidomimetics down-regulate TORC1-S6K1
signaling under starvation conditions in HeLa and
MCF-7 cells.
Thus, to corroborate the finding that the RIM15
kinase is down-regulated in yeast cells, and consequently
the response to nutrient starvation altered by FTI treat-
ment, we investigated the level of RPS6 phosphorylation
in HeLa and MCF-7 cells treated with 5 μM FTI-277.
We choose this compound and concentration here
essentially for three reasons: i) most of the work per-
formed with FTI peptidomimetics in mammalian cells
were performed with this compound; ii) when we
started this particular study FTI inhibitor I was no
longer commercially available; iii) 5 μM FTI-277 was
previously reported to exert an antiproliferative action
on HeLa and MCF-7 cells [3,4,8].
The state of RPS6 phosphorylation (PhoS6) in FTI-277
treated (FTI277) and untreated (NT) cells during serum
starvation was determined by automated high-throughput
fluorescence microscopy using the ScanR microscopy sta-
tion (Olympus) for acquisition and multiparametric
Figure 4 Multidrug transporter GFP-Pdr5 recycling is affected by FTI treatment of wt cells. A, fluorescence (upper panels) and DIC (lower
panels) images of K699 cells expressing Alr1-GFP or Gap1-GFP proteins. B, Representative fluorescence images of cells expressing PDR5-GFP with
plasma membrane (PM) or endosomal (END) localization are shown in the right panels. Images were taken in a blind fashion at time 0 h (T0) or
2 h (T2 h) after 10 μM FTase inhibitor addition and at least 100 cells were counted per sample. The graph on the left represents the increase (%)
of END-type over PM-type cells observed in FTI-treated versus untreated cells. The values are the mean of 3 independent experiments. Bar
indicates standard deviation. 10 μM FTase inhibitor I (+FTI); untreated (NT).
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analysis of images (HT/HCA; Figure 5). For this, cells
were seeded in five-well replicates in a 96-well plate. The
cells were left to adhere for 24 hours prior to the addi-
tion of 5 μM FTI-277 under starvation conditions as pre-
viously described by [39]. After 48 hours of treatment,
sixteen images were acquired randomly from each sample
using the RFP filter cube (U-MRFPHQ Olympus) to
detect the anti-PhoS6 antibody conjugated to Alexa-
Fluor555 and using the DAPI filter (Olympus) for
Hoechst-stained nuclear DNA (Figure 5A and 5B). Cells
were counted and cell cycle distribution established based
on the Hoechst mean intensity and total intensity signal/
area. Then, RPS6 phosphorylation levels were evaluated
based on the mean intensity values of treated compared
to untreated samples in the RFP channel. Overall, at least
600 cells per condition were counted and the PhoS6
levels were analyzed on the whole population using a
mask containing both cytosol and nuclei, or calculated
only considering the fluorescence intensity within the
main mask (nuclear area).
We observed that FTI-277 reduced the overall PhoS6
signal, corresponding to phosphorylated RPS6, by 23.6%
in HeLa cells and by 28.8% in MCF-7 cells compared to
untreated cells. A closer inspection of the RPS6 distribu-
tion with the area containing the highest PhoS6 signal
reveals that FTI-277 treatment reduced the number of
cells present in this gate by 54% in HeLa cells and by
37.6% in MCF-7 cells compared to the respective
untreated samples (Figure 5C respective panels).
All together, these analyses show that in yeast an FTI
peptidomimetic down-regulates the transcription of
genes acting at the cross-roads of the RAS/PKA and
TORC1-SK6 pathways regulating ribosomal protein
expression and cell cycle progression in response to
nutritional stress and starvation. This response is con-
served in mammalian cells [36]. Indeed, our data show
that the TORC1-SK6-dependent phosphorylation of
RPS6 (p70) is strongly down-regulated by FTI-277 dur-
ing starvation.
Transcriptional deregulation of TOR-responding genes as
well as of central components of the MAP-kinase
pathway and tumor suppressor genes are features of
Δram1 cells
We analysed the expression profile of Δram1 cells and
compared it to that of the isogenic BY4741 cells and to
FTI-treated cells to highlight the effects of chronic ver-
sus acute inhibition of FTase. As previously mentioned,
Δram1 cells deleted for the gene encoding the RAM1
subunit of the FTase enzyme completely lack FTase
activity.
Cell growth, RNA extraction and array preparation
and analysis were performed in parallel with those
reported above to minimise experimental differences
such as media, growth conditions, methods of RNA
extraction or cDNA labelling and the microchip batch.
Ninety-nine and thirty-eight transcripts were identified
to be up-regulated or down-regulated, respectively, at
least 0.5 fold in Δram1 cells compared to BY4741 cells
(Additional file 2: Table S8; T-Test set 80% confidence).
Consistent with the fact that GGTase I prenylates FTase
substrates in Δram1 cells [1], up-regulation of CDC43/
CAL1, encoding the beta subunit of the GGTase I, was
observed in Δram1 cells.
Clustering the up-regulated hits for compartment of
action, using Super GO-Slim Component (Additional
file 2: Table S9), or for biological process (Additional
file 2: Table S10), using Super GO-Slim Process at the
SGO database, shows that the frequency of gene clusters
falling in the same compartment of action or sharing a
function in the same biological process is similar
between Δram1 and FTI-treated cells (Figure 2A: Com-
partment of action and Figure 2B: biological processes).
Unlike the 10 μM FTase inhibitor I-treated cells, no
statistically significant group (p-value < 0.01) sharing a
similar function within the nucleus was identified. Bin-
ning the 99 up-regulated hits in Δram1 cells for biologi-
cal process shows that 5.1% of the transcripts encode
proteins acting in signal transduction (CDC43, GPG1,
SDP1, TEP1, TPK1; Figure 2B and Additional file 2:
Table S10). We note that only 2.9% of the genes fall
into this category in the case of FTI-treated cells (Addi-
tional file 2: Table S6).
Within the signal transduction group (Additional file
2: Table S10) of up-regulated genes in Δram1 cells were
the catalytic subunit of PKA (the cAMP-dependent pro-
tein kinase type 1, TPK1), the protein-tyrosine phospha-
tase SDP1 and the yeast orthologue of the human tumor
suppressor gene PTEN (the TEP1 gene).
Sdp1p, a stress-inducible dual-specificity MAP kinase
phosphatase is induced by several stress conditions in
Table 2 Plasmids list
Plasmid construct Marker Replication Origin Reference
Myo1-GFP pRS316 URA CEN E. Bi
Cdc3-GFP pRS316 URA CEN G. Ammerer
Mrs6-GFP YEp352 URA 2 μ [53]
Fba1-GFP pUG35 URA CEN S. Wacha
Ras2-GFP pUG34 HIS CEN This work
Sec2-GFP pUG35 URA CEN [50]
Sec4-GFP pUG36 URA CEN [50]
Mlc1-GFP pUG36 URA CEN [50]
Alr1-GFP pUG34 HIS CEN A. Graschopf
Pdr5-GFP pRE104 HIS CEN [32]
Gap1-GFP pTPQ99 URA CEN C. Walch-Solimena
Sec7-RFP pTPQ127 LEU CEN C. Walch-Solimena
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an Msn2p/Msn4p-dependent manner [40], which nega-
tively regulates the Slt2/MPK1 serine/threonine mito-
gen-activated kinase by direct dephosphorylation. In
yeast, the Slt2p/MPK1 kinase is part of a signaling cas-
cade required to maintain cell wall integrity and pro-
gression through the cell cycle acting downstream of
PKC pathways [41]. Sdp1p is also capable of depho-
sphorylating the closely related mammalian MAPK
ERK2 [42]. The yeast counterpart of the tumor suppres-
sor gene PTEN (phosphatase and tensin homologue
deleted on chromosome 10), tensin-like phosphatase
TEP1, was also identified. In mammals PTEN is either
deleted or inactivated in a very high percentage of
breast, endometrial, brain, and prostate cancers. Homo-
zygous deletion of PTEN in mice is embryonic lethal
and mice with only one functional copy of the gene are
more likely to develop tumors [43]. Thus, chemical and
genetic FTase inhibition elicits both common and non-
overlapping transcriptional responses. The common set
of responses involves genes in the TORC1-S6K1 signal-
ling pathway, but differently from the FTIs, key compo-
nents of Ras/PKA pathways are affected by RAM1
deletion. The chronic versus acute FTase inhibition
response reflects the fact that we set the FTI concentra-
tion at a level that does not affect Ras pathways while
this pathway is necessarily altered in Δram1 cells.
Within the 5.1% of transcripts up-regulated and falling
within the transcription category (AFT1, CEG1, DST1,
SOH1, TOS8) there are mainly RNA polymerase II tran-
scriptional regulators (Additional file 2: Table S10),
Figure 5 FTI-277 treatment reduces the phosphorylation of ribosomal protein S6 in HeLa and MCF-7 cells. The levels of RPS6 (p70)
phosphorylation in HeLa and MCF-7 cells were measured using the ScanR analysis software based on the intensity of AlexaFluor 555-conjugated
PhoS6 antibody (Ser 235/236: Cell Signalling) recorded from images acquired from samples treated with 5 μM FTI-277 (panel FTI-277) or not
treated (panel NT) in the presence of 0.1% serum for 24 h. Five wells per condition were considered. Cells were seeded in a 96-well plate and
fixed and stained as described in Methods. Sixteen images were acquired randomly per well with a 20× objective using the RFP filter. The mean
intensity within the red channel was automatically calculated by ScanR analysis software considering at least 600 cells. A, Images representative
of FTI-277-treated and untreated HeLa cells stained with PhoS6 antibody and Hoechst, single and merged pictures are shown. B, Images
representative of FTI-277-treated and untreated (NT) MCF-7 cells, stained as in (A); C, Analysis of the distribution of the phosphorylated RPS6
population in HeLa and MCF-7 cell lines. Hoechst staining was used for cell identification (main mask), as described in Methods. The minimal
threshold of the PhoS6 signal was set at mean intensity 43.8 for HeLa and at 63.8 for MCF-7 cells based on the background intensity. The
percentage of cells having a PhoS6 signal localised within this gate was calculated and plotted in the graph.
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while in FTI-treated cells this category comprised MDR
gene transcription regulators.
Similarly to the case of FTI-treated cells, 8.1% of genes
up-regulated in Δram1 cells fall into the cell cycle cate-
gory (Figure 2BΔram1 and Additional file 2: Table S10,
cell cycle) and network analysis by STRING (Figure 3B)
identified CLN3, DST1 and MAD1 as forming a
network having nodes at the catalytic subunit of the
cyclin-dependent kinase CDC28, the spindle checkpoint
protein MAD2 and the RNA polymerase II subunit
RPB1. MAD1 (Mitotic arrest deficient protein 1) is a
central component of the spindle assembly checkpoint,
thought to recruit MAD2 to unattached kinetochores.
Among the 38 down-regulated genes (Additional file 2:
Table S8, down-regulated) in Δram1 cells acting in the
cell cycle and signal transduction (Additional file 2: Table
S11) were the mitogen-activated protein (MAP) kinase
kinase kinase BCK1, which acts in the protein kinase C
signaling pathway, the cytoskeletal motor DYN1, required
in anaphase for mitotic spindle elongation, and SAC7,
the GTPase activating protein (GAP) for Rho1p.
Sac7p acts as a negative regulator of the geranylgera-
nylated small GTPase RHO1 that plays an essential role
in signaling to the actin cytoskeleton. Moreover, Sac7p
is linked to the cell cycle, being a potential Cdc28p sub-
strate. Interestingly, deletion of SAC7 (Δsac7) suppresses
tor2 mutations and increases MPK1 activation [44].
Thus, one might expect that the constitutive down-regu-
lation of SAC7, observed in Δram1 cells, must result in
MPK1 hyperactivation. That this is the case is supported
by the above-mentioned up-regulation of Sdp1p. Clearly,
it will be the balance between these two opposite activ-
ities on the MPK1 protein that will finally regulate
Δram1 cell proliferation and stress responses. The
human tumor suppressor gene DLC-1 is a Sac7 family
member. DLC-1 is normally expressed in many adult
human tissues, and is down-regulated or absent in a
number of common human cancers, including breast,
colon, ovarian, uterine, gastric, lung, pancreatic, pros-
tate, renal and nasopharyngeal tumors [45].
GGTI-298 treatment deregulates genes of unknown
function
The specificity of the response to FTIs was validated by
analysing the transcriptional signatures of BY4741 cells
treated or not with 10 μM GGTI-298.
As mentioned above, GGTI-298 is a cell permeable
compound prevalently targeting GGTase I. Although no
effect on the growth of yeast cells was observed in liquid
or solid medium at this concentration, this does not
necessarily mean that yeast are insensitive to this com-
pound in our assay conditions.
After nomalization and statistical filtering with lowess
and setting the T-test at 80%, 86 genes were found to
be up-regulated in GGTI-298-treated yeast cells (Addi-
tional file 2: Table S12).
Binning these genes for compartment of action (Figure
2A panel GGTI and Additional file 2: Table S13) or for
biological process (Figure 2B panel GGTI and Addi-
tional file 2: Table S14) showed that the overall tran-
scriptional pattern differed markedly from that obtained
by chemical or genetic inhibition of FTase activity. The
most striking outcome from these analyses was that the
majority of genes up-regulated by GGTI-298 have an
unknown localization.
In particular, we note that of the 86 up-regulated genes
only 4.7% are involved in the cell cycle (Figure 2B and
Additional file 2: Table S14), compared to 8.7% and 8.1%,
in FTI and Δram1 cells, respectively. Binning the up-
regulated hits localised within the nucleus (Additional file
2: Table S15) for biological process using GoTerm Pro-
cess tool at SGD showed that a significant (p-value cutoff
< 0.01) group of genes act in RNA metabolic processes.
Similar criteria applied to Δram1 cells gave no hits while
a significant group of proteins acting at the kinetochore
was observed in the case of FTase inhibitor 1.
The 95 genes showing statistically significant down-
regulation in GGTI-298 treated cells (Additional file 2:
Table S12) were binned by compartment of action,
(Additional file 2: Table S16), and then classified by bio-
logical process, using GO Term Finder at SGD, produ-
cing a list of proteins that reside in the nucleus and are
involved in rRNA maturation (Additional file 2: Table
S17). A group functioning within the endoplasmic reti-
culum was also identified that act in lipid metabolism
(Additional file 2: Table S18). It is also worth noting the
down-regulation of CDC43, a subunit of GGTase-I,
among the genes down-regulated in GGTI-298 treated
cells confirming that GGTI-298 affects GGTase I func-
tion not only by inhibiting enzyme activity but also by
down-regulating gene expression.
In conclusion, changes in the regulation of the yeast
transcriptome in GGTI-298 treated cells do not corre-
late with those observed in FTase down-regulated cells.
Effects of FTI-277 treatment on Aurora A kinase
localization in HeLa cells
Network analysis of FTase inhibitor I-treated cells sug-
gested Aurora Kinase IPL1 as one of the hubs of the
cell cycle gene transcript network. Entry into mitosis is
a highly regulated process promoted by the activated
Cyclin B1/Cdk1 complex. Activation of this complex is
partially dependent on the protein kinase Aurora-A.
The phosphatase PPA2 promotes Aurora A degradation
by dephosphorylating serine 51. The yeast Aurora A
homologue Ipl1p was originally identified through muta-
tions leading to increased chromosome mis-segregation
[46].
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To determine if FTI-277 changes Aurora A activity/
localization, HeLa cells were seeded in 96-well plates,
left to adhere and then grown for a further 48 hours in
the presence of 2 μM FTI-277 or in mock medium as
described in Methods. The localization of Aurora A was
then evaluated in ten wells by determining the Aurora
A localized on or near nuclei using FITC-fluorescently
labeled Aurora A antibody on fixed cells (Figure 6). The
analysis was performed using the ScanR automated
microscopy and software platform (Olympus) that allows
a multiparametric analysis of fluorescence images and
their statistical analysis.
We set masks that allow the identification of Aurora
A spots at the centrosomes as well as the determination
of the mean intensity FITC (Aurora A) and Hoechst
(DNA) channel within the nuclear and cytosolic area.
Data analysis showed that FTI-277 treatment of HeLa
cells results in a marked reduction of Aurora A localiza-
tion at centrosomes during the G2-M phase (Figure 6A
and 6B), a stage at which Aurora A expression peaks
[47], with only 32% of G2-M cells (200 cells counted for
every condition) showing Aurora A localized to centro-
somes in FTI-277-treated cells compared to 52% in
untreated cells. The Aurora A localization in FTI-277-
treated cells was generally more diffuse over the whole
cell. This difference could not be observed over the
entire population of cells, as the cells were not synchro-
nized and were mainly in G1, when Aurora A is difficult
to detect [47]. These observations support the array data
and imply that FTIs can affect chromosome segregation
by impacting on Aurora A degradation and/or
localization.
Cell cycle analysis of FTI-277-treated HeLa and MCF-7
cells
Progression through the cell cycle is a carefully regu-
lated process in all eukaryotes. Periodic activation of
cyclin-dependent kinases (CDKs) is required to pass
through START and thus for commitment to the next
round of cell division. The comparative analysis of the
protein networks acting in the cell cycle also suggested
that FTIs might impact on entry into the cell cycle, pos-
sibly by acting on G1 cyclins and/or on the cyclin-
dependent-kinase Cdc28 as these proteins were at the
hub of genes deregulated in FTI-treated and in Δram1
cells.
Thus, we further studied the effect of FTI-277 on cell
cycle entry and progression in HeLa and MCF-7 cancer
cell lines using image analysis and the ScanR platform
to measure Hoechst total intensity distribution through-
out the cell cycle in 5 μM FTI-277-treated and
untreated cells. As above, the effects of FTI-277 on cell
cycle progression were analysed in 96-well plates, where
cells were grown for 48 hours in the presence (FTI) or
absence (NT) of FTI-277. After fixation, nuclei were
stained with Hoechst and the percentage of cells in the
G1, S or G2 phase of the cell cycle was calculated based
on the total intensity Hoechst signal present within the
nuclear region using the ScanR analysis software. More
than 850 cells, seeded in a total of five wells, were
counted for each experiment and the mean of two inde-
pendent experiments were considered.
HeLa and MCF-7 cells have different degrees of sensi-
tivity to FTI-277, MCF-7 being the most sensitive [7,48].
The results show that FTI-277 treatment affects the cell
cycle distribution of both HeLa and MCF-7 cells but in
an opposite fashion. Approximately a 2% increase in the
Figure 6 FTI treatment impairs the localization of Aurora A in
G2-M cells. HeLa cells were seeded in 10 wells of a 96-well plate
and grown as indicated in Methods. After 48 hours treatment with
2 μM FTI-277 (FTI-277) or no treatment (NT), the cells were fixed
and stained with an antibody recognising aurora A (aIAK1; BD
Biosciences) and the cell cycle distribution was calculated based on
the total intensity signal in the Hoechst channel within the nuclear
area using the ScanR analysis software. Ten wells were considered
per sample and 12 images were acquired randomly in each well. A,
Representative cells falling within the G2/M gate of treated (FTI-277)
or untreated (NT) HeLa cells. B, The graph shows the percentage of
G2/M phase cells that have Aurora A localized in spots at
centrosomes in FTI-277-treated cells and in untreated cells. Two
hundred randomly chosen cells were counted for each condition.
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G1 population, compared to the untreated control, was
observed in MCF-7 cells while a comparable decrease
was observed in HeLa cells (Additional file 2: Figure S6).
The G2 population in both cell types showed the
expected reciprocal changes (Additional file 2: Figure
S6A). These data indicate that FTI acts at either the G1/
S or G2/M transition depending on the cell type.
To gain further insight into the G2/M phenotype of
HeLa cells, we measured histone H3 phosphorylation at
serine 10 using a phosphospecific antibody (aPhoH3,
Additional file 2: Figure S6C). Histone H3 has a key role
in the folding and inter-association of the chromatin
fibers prior to and during mitosis. Entrance into mitosis
is accompanied by hyperphosphorylation of Ser-10 of his-
tone H3. Mitogenic stimuli, mediated by Ras activation,
are also accompanied by an increase in Ser-10 phosphor-
ylation of H3. Under the conditions used in this study,
only a minor proportion of the total cellular population
was found to be in mitosis. However, an increase of 16%
in the number of mitotic cells, relative to untreated cells,
was observed in HeLa cells. No such effect was detectable
in MCF-7 cells treated in a similar manner in indepen-
dent experiments (Additional file 2: Figure S6B).
A careful inspection of the nuclear morphology of
HeLa cells throughout the cell cycle, by plotting the
mean intensity values of the Hoechst signal in the
nuclear area, identified a subpopulation of cells within
the G1 population with an altered nuclear morphology
in FTI-treated HeLa cells (Figure 7A). Although cells
with a similar area and mean intensity values of the
Hoechst signal are also present in the untreated (NT)
population (Figure 7B), they are few in number com-
pared to the FTI-treated cells (Figure 7C) and have no
nuclear morphological defects (compare respective gal-
leries in Figure 7A and 7B). The FTI-treated cell popula-
tion with nuclear morphological defects appears to have
an altered chromatin distribution within the nuclei,
DNA staining being absent over a large area within the
nucleus. Proper mitotic chromosome condensation is
essential for the correct segregation of sister chromatids
into two daughter cells. Typically, chromatin condensa-
tion becomes apparent in prophase and is maximal dur-
ing the stages of mitosis. As mentioned previously,
Histone H3 Ser-10 phosphorylation is a signature of
mitotic entrance. The presence of a defect in chromatin
distribution in treated HeLa G1 cells could be therefore
indicative of a premature activation of histone H3 at G1
and be the cause of the accumulation of G2 cells.
Therefore, we measured the level of activation of his-
tone H3 within the population with an altered morphol-
ogy and compared it to the intensity values observed in
the total population. No major changes were observed
in the mean intensity values of aPhoH3 present in this
population compared to the total population (Figure 7D,
aPhoH3 panel). Thus the chromatin distribution defects
in FTI-treated HeLa G1 cells is unlikely to be due to a
defect in chromatin packaging dependent on H3 histone
activity.
A second possibility is that the nuclei have morpholo-
gical alterations that impair the normal distribution of
uncondensed DNA within the nuclei. We therefore
fluorescently immunostained the cytosol and nuclei with
an anti-p21 kinase (PAK) antibody (aPak-C19) in the
same samples. As can be best appreciated by the merged
images in the gallery of cells randomly and blindly cho-
sen by the program among all cells present in the gated
population with a morphologically defective area, aPak-
C19 distributes equally in normal nuclei and in nuclei
with a DNA hole in the centre (Figure 7D, aPAK
panel). Although a more careful three-dimensional ana-
lysis of these cells is required, these data suggest that
nuclei have morphology defects that cause the chroma-
tin distribution defects observed.
In summary, FTI treatment in yeast as well as in
mammalian cancer cell lines affects chromosome segre-
gation by altering Aurora A localization and reduces
progression through the cell cycle in HeLa and MCF-7
cells. High content analysis of the images obtained from
HeLa cells show that a significant proportion of the G1
cell population (about 6%) experiences chromatin distri-
bution defects that do not involve H3 hyperphosphory-
lation or distribution changes but are more likely due to
nuclear envelope morphology defects.
Conclusions
A decade of preclinical and clinical studies has shown
that chemically different FTIs act in a well-defined
mechanistic-driven manner but the signalling modules
that are affected by FTase down-regulation have
remained unclear so far [5,8]. Here we have shown that
FTI peptidomimetics affect the chromosome segregation
machinery at the level of the kinetochore and Aurora A
mis-localization is one of the features of FTI-treated
cells. This is expected to result in replication defects
that might account for the overall FTI antiproliferative
action.
A second target of FTI-induced transcriptional
changes (up- or down-regulation) are key downstream
regulators of transcriptional responses that control ribo-
somal expression and cell cycle progression mediated by
TORC1/Sch9/S6K1 signalling pathways. This effect was
observed in both FTI-treated and Δram1 cells indicating
that FTase down-regulation is per se a “cellular stress
signal” that is monitored by a specific intracellular
machinery that impinges on the TORC1/Sch9/S6K1 sig-
nalling pathways. Further data are required to conclu-
sively show that this is the case but the data reported
here strongly support this view.
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The PI3K/Akt/mTOR pathway is a survival pathway
often constitutively activated in many types of cancer
[35]. Indeed, a synergistic action of rapamycin and clini-
cally relevant FTIs has been previously observed [3].
Thus, an effect of FTI in down-regulating mTOR signal-
ing might account for its antiproliferative action in
malignancies in which TORC1/S6K activation plays an
important role. That this is the case is also suggested by
the finding that the clinically-relevant FTI, SCH66336
(lonafarnib), inhibits mTOR signaling. It has been sug-
gested that this might be due to defective RheB farnesy-
lation upon FTI treatment [39]. The fact, however, that
the yeast RheB homologue does not appear to act
upstream of TOR1 suggests that the transcriptional
deregulation of TOR-downstream effectors as seen in
this study does not depend on poor prenylation of a
yeast RheB-like protein.
Interestingly, many genes transcriptionally deregulated
in FTase-deficient cells belong to the category of tumor
suppressors. These observations support the view that
FTI treatment might result in different responses
depending on the role that PTEN or the DLC-1 tumor
suppressor has in a given cancer pathology.
Finally, it is noteworthy that the up-regulation of the
multidrug resistance machinery occurs solely in FTI-
treated cells. Due to the high number of MDR and ABC
transporter genes in mammalian cells, as well as
uncertainty as to the direct orthologues of the yeast
Pdr5 and Pdr1 genes, it was not possible to directly reci-
procate this finding in mammalian cells. However, sup-
porting our array and image analyses, a marked up-
regulation of ATP11a but also decreased expression of
the ABC transporter ABCA1 has been associated with
SCH66336 resistance in murine lymphoblasts [24].
Others have reported that Tipifarnib, another FTI used
in clinical trials, has an inhibitory effect on MDR trans-
porter activity via an as yet unknown mechanism [49].
Curiously, however, FTI-277 reduces endogenous
expression of MDR1 in the human colorectal cancer
cells HCT-15 and SW620-14 [28]. All together, the
yeast and mammalian data suggest that FTI inhibitors
impact on the multidrug resistance response at different
levels and different members of the ABC transporter
superfamily are involved. Thus, the MDR response has
to be carefully evaluated case-by-case upon FTI
treatment.
In conclusion, this study shows that FTase inhibition
activates, in yeast and in mammals, a well-defined tran-
scriptional response. We propose that defects in FTase
activity are per se a cellular stress, normally monitored by
Ras/PKA and TOR/Sch9/S6K1-responding genes. Further-
more, this study shows that even suboptimal concentra-
tions of FTI drugs can boost the detoxification pathways
leading to MDR up-regulation and thus to FTI resistance.
Figure 7 Nuclear morphology in HeLa G1 cells treated with FTI-277. The nuclear morphology of HeLa cells, grown and treated as described
in Methods, was analysed throughout the cell cycle by plotting the mean intensity signal in the Hoechst channel (x) over the nuclear area (y)
using the ScanR analysis software. G1 cells with an altered nuclear morphology were identified in FTI-treated samples and gated to define the
mean intensity and area coordinate of this population. A gallery of images of this population is shown in (A). The same region of untreated (NT)
cells is shown in (B). C, the fold change of G1 cells with an altered nuclear morphology in FTI-277 treated versus NT cells present in the gated
population was calculated and plotted in the graph; the mean and the standard deviation of two independent experiments are given. D, the
upper panel shows the software mask that identifies the nuclei in the images. The lower panel shows galleries of nuclei in FTI-277-treated cells
present in the gated population, stained with Hoechst to label nuclei and with anti-Pak (aPaK) and anti-Phospho-histone H3 (aPhoH3) antibody
as indicated
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Methods
Yeast strains, drug compounds, plasmid constructs,
media and growth conditions for yeast cells
Strains, plasmids and oligonucleotides are listed in Table
1, Table 2 and Table 3, respectively. BY4741 and
YDL090C Δram1 (isogenic with BY4741) strains were
purchased from EUROSCARF, the K699, W303 and
Δras2 strains were a gift from Prof. Kim Nasmyth (Uni-
versity of Oxford). Media, transformation and genetic
manipulation as well as molecular procedures used were
previously described [50]. Unless otherwise specified,
yeast cells were grown at 27°C with agitation in YPD
medium or SD medium lacking the appropriate amino
acids for plasmid selection as previously described [50].
FTase inhibitor I (Cat.N 344510), FTI-277A (Cat. No.
344555), GGTI-298 (Cat. No. 345883) and Manumycin
A (Cat.N 444170) were purchased from Merck-Calbio-
chem (see http://www.merck-chemicals.it/life-science-
research for product specificity). GFP-Ras2pUG34 was
constructed by polymerase chain reaction (PCR) using
the High Fidelity TAQ polymerase (Roche) and the oli-
gonucleotides Ras2Fw and Ras2Rv listed in Table 3. The
PCR fragments were purified, digested with BamHI and
EcoRI and cloned in the same sites of vector pUG34 as
previously described [50].
Fractionation of cell extracts
Cells were grown in the presence or absence of 10 μM
FTase inhibitor I (Merck-Calbiochem) in SD-HIS as
described in the text. The FTI was added to exponen-
tially growing cells at OD600 = 0.2 and the cells were
harvested at OD600 = 0.6. Crude extract preparation
using glass beads, fractionation by differential centrifu-
gation and Bradford assay to estimate protein concen-
tration were performed as previously described [50].
Briefly, fractionation of crude extracts was carried out
by centrifugation at 15.400 × g for 30 minutes at 4°C.
The resulting P15400 × g fractions was resuspended in
buffer I (10 mM Tris-HCl pH 8.0, 1 mM PMSF, 1 tablet
protease inhibitor, [Roche]) and then in 2× SDS sample
buffer (20% glycerol, 2% SDS, 125 mM Tris-HCl pH 6.8,
0.1 mg bromophenol blue) and boiled prior to separa-
tion by SDS-PAGE and processed for immunoblotting.
Anti-GFP antibody (Roche) was used to detect GFP-
Ras2. Western blotting, immunodetection and ECL
detection (SuperSignal, PIERCE) and exposure to X-ray
films (KODAK-AR) were performed as previously
described [50]. Results were analysed and quantified on
a densitometer Pharos FX using the Quantity One soft-
ware (BioRad). When indicated the amounts of proteins
transferred on the nitrocellulose membrane were deter-
mined with Ponceau S staining as previously described
[51].
Fluorescence microscopy in yeast cells
Typically, cells expressing the indicated GFP-tagged
protein were grown to stationary phase overnight in
the appropriate selective SCD media as previously
described [50]. The cultures were then re-inoculated in
fresh media at OD600 = 0.1 and grown with shaking at
the temperature indicated in the text. The indicated
FTI was added (treated) or not added (control) at
OD600 = 0.2 (T0). Samples were then taken at the indi-
cated time points. At each time point cells were har-
vested by centrifugation and, unless otherwise
indicated, immediately inspected. Images were taken
with a Nikon TE 2000 inverted microscope equipped
with a 60× objective NA1.4 and CCD camera using the
appropriate filters.
Microarray design, acquisition and analysis
Array source and experimental design: Yeast Type
6.4k4 arrays (University Health Network http://www.
microarrays.ca) were used. These are double spotted
glass arrays with 6,240 different yeast ESTs and 160
Arabidopsis genes as controls. All materials spotted are
in the form of double stranded DNA and are coupled
Table 3 Oligonucleotides list
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to the slide matrix. The DNA is derived from PCR
amplification of synthetic EST clones. Type of Array:
Yeast; Probe Set Arrayed: Y 6.4k4; Arrayer Used:
SDDC24; Slide Batch Number: 701; Slide Batch Code:
24030514; Slide Type: Corning CMT-GA; Manufac-
turer Lot Number: 29102000. Further information on
array design is available at the manufacture’s web site
(http://www.microarrays.ca/products/microarrays_lay-
outs.html. Microarray acquisition, normalization and
visualization: Axon ScanArray 4000 and the Genepix
version 6.0 (Molecular Devices) was used to acquire
images, quantification, gene mapping, normalisation
and chip quality control. Data normalization included
a manual erase of the spots corresponding to “dirty”
spots on the images. Moreover, we excluded the spots
with a high percentage of saturated pixels and with a
weak signal over background, and all spots flagged
absent or bad. All data were deposited at the ArrayEx-
press Repository at EBI http://www.ebi.ac.uk/microar-
ray-as/ae/ with accession number: E-MTAB-215,
E-MTAB-216 and E-MTAB-217 for the expression
profile of S. cerevisiae after FTI treatment, genetic
block of FTase and GGTI298 treatment, respectively.
The Gene@work software (IBM research; http://www.
research.ibm.com/FunGen/FGGenesAtWorkDoc.
html#Visualizing) was used to visualize the expression
levels in each array. The color plots derived from each
array are given in Additional file 2: Figure S1, S2, S3
and the respective Figure legends in Additional File 1).
Briefly, cDNA microarray measurements are made
using the two color fluorophores Cy3 and Cy5, where
one color corresponds to the control and the other to
the sample of interest. Dye swapping method was used
to minimize the effects of the differential incorporation
of these two dyes into the cDNAs derived from the
mRNAs. The measured values are reported as the loga-
rithm base 2 of the ratio (log2 ratio) of the two chan-
nels. The input data of the color plots in Additional
File 2 figures S1, S2 and S3 are .txt files containing the
log2 ratio of medians of the intensity signals from trea-
ted and untreated samples. These were calculated by
the Acuity software (Molecular Devices) from the low-
ess normalized .gpr files obtained from scanning the
microarrays by Gene Pix (Molecular Devices). Genes
flagged absent (too low intensity over background) or
flagged bad were excluded from the calculations.
Array statistical analysis and pattern recognition:
after acquisition by using GenePix6 software the .gpr
data generated were loaded onto the Acuity software
(Molecular Devices) for lowess normalization and T-
test statistical analysis. Four arrays for FTI, five arrays
for Δram1 and eight arrays for GGTI-298 were used
for statistical analysis. Only the spot signals that were
present in at least 60% of the analysed microarrays
were considered. The log2 ratio between the medians
of the treated and control and the mean of the log2
ratio among the various arrays was calculated. Only
genes having a log2 ratio corresponding to at least 0.5
fold over- or under-represented relative to control
were considered differentially expressed (Additional
files 1 and Additional file 2 tables). These data were
finally statistically filtered using Acuity software T-test
analysis. All genes with a p-value > 0.2 were excluded
to have at least 80% confidence in T-test analysis. The
hits were finally clustered according to the features
described in the text by using internet tools freely
available at SGD http://www.yeastgenome.org/GOCon-
tents.shtml and the default search value described
therein.
RNA extraction and cDNA labelling
Growth conditions for RNA extraction: Treated and
untreated cells were grown in parallel cultures, with
equal-size flasks and with the same stock of media, to
ensure that experimental growth conditions were equal
for each pair of tested strains. Growth conditions, shak-
ing and cell density were carefully controlled over time
until harvesting. Typically, cells were grown overnight in
a culture tube containing 3 ml YPD. The overnight cul-
tures were then re-inoculated in fresh media to OD600 =
0.1 in 100 ml flasks containing 30 ml YPD with (treated)
or without (untreated) 10 μM FTase inhibitor I or 10
μM GGTI-298 and harvested at OD600 = 0.8 for RNA
extraction. RNA extraction, cDNA labelling and micro-
array hybridisation: Total RNA, labelling and cDNA
hybridization onto the microarray was performed as
described by the array manufacturer http://www.micro-
arrays.ca/info/protocols.html and in Additional file 1.
Briefly, RNA extraction was performed following the
hot-phenol method [52]. Reverse transcription was per-
formed using Superscript II (Invitrogen) in the presence
of either Cy3- or Cy5-dCTP (Amersham) and the manu-
facture’s standard conditions for the other nucleotides.
Dye swapping was used to minimise errors due to
different incorporation capabilities of Cy3 and Cy5
(Amersham). At least three independent RNA extrac-
tions were performed for each pair of tests.
Quantitative Real-Time PCR
To validate the array normalization and statistical analy-
sis for the FTI arrays we performed quantitative Real-
Time PCR. For this, ten genes were randomly chosen
among the up- and down-regulated hits of FTase treated
cells. As an endogenous control we used the YBR159W
gene. Primers were designed using the Primer Express®
software from Applied Biosystems. The amplification
efficiency of each pair of primers was tested using serial
dilutions (5 dilutions) of genomic DNA as template and
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amplification under standard conditions (see below).
Efficiency was calculated as Eff = 10(-1/slope) - 1 × 100.
All primer pairs had an efficiency between 90-110%, and
showed a single peak in dissociation curves. Primer spe-
cificity was also controlled using agarose gel electro-
phoresis. Total RNA was isolated from yeast cells
treated or not with FTase inhibitor I (Merck-Calbio-
chem). The cells were in the exponential growth phase:
the drug was administrated at OD600 = 0.2 and the
RNA was extracted at OD600 = 0.8. Reverse transcrip-
tion of 2 μg of DNase-treated RNA was performed
using random primers and Taqman® Reverse Transcrip-
tion Reagents (Applied Biosystems) according to the
manufacturer’s instructions. Amplification reactions
were performed in a volume of 50 μl in the presence of
SYBR Green PCR Master Mix (Applied Biosystems), 300
nM of each primer, and 2 μl of cDNA on an ABI
Prism® 7900 HT device. Amplification conditions were
50°C for 2 min, 95°C for 10 min, followed by 40 cycles
of 95°C for 15 sec and 60°C for 1 min. Each amplifica-
tion was run in triplicate, and two independent experi-
ments were performed. Relative expression levels were
calculated automatically by the ABI Prism® 7900 HT
software with the ΔΔCt method using the YBR159W
gene as the endogenous control. The up- or down-regu-
lation of five genes has been confirmed by this techni-
que and another four show a similar but smaller
response to that determined by microarray analysis.
Human cell culture, treatments, imaging and cell cycle
analysis
The HeLa cell and MCF-7 cell lines were purchased
from ATCC. HeLa cells were grown in MEM supple-
mented with 10% foetal calf serum (FCS), 2 mM L-glu-
tamine, penicillin, streptomycin and non-essential amino
acids, at 37°C in 5% CO2. Media, serum and reagents
for tissue culture were purchased from GIBCO™ (Invi-
trogen). MCF-7 cells were grown in MEM supplemented
with 10% FCS, non-essential amino acids, 1 mg/100 ml
insulin, 8.4 mg/100 ml NaHCO3 at 37°C in 5% CO2.
HT/HCA Image analysis: typically 5000 HeLa and
10000 MCF-7 cells were seeded in 96-well Greiner-Bio-
One plates and left to attach overnight in their respec-
tive media. The indicated amounts of FTI-277 or the
vehicle (DMSO) were added and the cells were grown
for a further 48 hours. Cells were then washed in 1×
phosphate-buffered-saline (PBS) and fixed for 10 min
with 4% paraformaldehyde in 1 × PBS, and permeabi-
lized for 30 min in blocking buffer [0.05% saponin, 0.5%
bovine serum albumin (BSA), 50 mM NH4Cl and 0.02%
NaN3]. Nuclei were stained with Hoechst (1:1000 in
blocking buffer), washed three times and inspected
using a 20× objective of the ScanR imaging platform
(Olympus). Sixteen images were acquired randomly per
well. For cell cycle analysis at least three wells per con-
dition were considered for statistical analysis of the
HeLa and MCF-7 cells. For all the others five wells were
considered.
Determination of mitotic cell number: fixed cells were
incubated for 75 min with a-PhosphoH3 pSer10
(Sigma) diluted 1:100 in blocking buffer, washed three
times in 1 × PBS, and further incubated for 30 min with
anti-mouse Alexa488 conjugates (Molecular Probes)
diluted 1:500 in blocking buffer, washed three times and
inspected using the ScanR microscope (Olympus). For
determination of Pak1/2/3 localization, an anti-Pak C19
antibody (Santa-Cruz) and anti-rabbit Alexa546 were
used.
For determination of Aurora A localization, an anti-
IAK1 (BD Biosciences) and anti-mouse Alexa488 conju-
gates (Molecular Probes) were used. HeLa cells were
treated for 48 hours with 2 μM of FTI-277 or with the
vehicle, and then fixed using the procedure indicated
above.
To determine the phosphorylation of ribosomal pro-
tein S6, an Alexa555-conjugated anti-PhosphoS6 anti-
body (Cell Signaling) was used. Typically 4000 HeLa
and 8000 MCF-7 cells were seeded in five wells per
experimental condition. Cells were left to attach over-
night, and treated with 5 μM of FTI-277 or with the
vehicle for 24 hours in starvation medium (0.1% FCS).
Cells were fixed, washed and probed with Hoechst
and processed for ScanR acquisition as described
above. Quantification and statistical analysis were per-
formed with the in-built ScanR analysis software
(Olympus).
Additional material
Additional file 1: Additional methods and additional data figure
legends: detailed information of the methodology used for
microarray acquisition and analysis; figures and tables legends of
data shown in Additional file 2.
Additional file 2: Additional figures and tables: supplementary
tables, figures and graphics of the expression profiling results.
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